NCT06881368 (CARESS Cohorte) is a clinical trial in Susac Syndrome, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT06881368?

NCT06881368 is sponsored by Assistance Publique - Hôpitaux de Paris.

What condition does NCT06881368 study?

NCT06881368 studies Susac Syndrome.

Is NCT06881368 still recruiting?

NCT06881368 is currently not yet recruiting. Last updated 18 March 2025.

Last reviewed 2025-03-18 · How we verify

NCT06881368: CARESS Cohorte

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phenotypic and Etiological Characterization of Susac Syndrome

Not yet recruiting Last updated 18 March 2025

What this trial tests

trial in Susac Syndrome in 180 participants. Not yet recruiting.

Timeline

30 March 2025

Primary endpoint
30 March 2037

30 March 2038

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	180
Start date	30 March 2025
Primary completion	30 March 2037
Estimated completion	30 March 2038
Sites	1 location across France

Conditions studied

Susac Syndrome — all drugs for Susac Syndrome →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Susac Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SUSAC's Syndrome (SS) is characterized by the clinical triad of encephalopathy, hearing loss, and retinal artery branch occlusions. Since the first description of SS in 1979, hundreds of patients with SS, mostly young women, have been reported. However, comprehensive epidemiological, clinical and etiological features of SS have never been specifically addressed so far.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06881368 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 18 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06881368.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing